blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3930763

EP3930763 - MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.12.2021
Database last updated on 10.07.2024
FormerThe international publication has been made
Status updated on  04.09.2020
Formerunknown
Status updated on  01.04.2020
Most recent event   Tooltip29.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2022/01]
Inventor(s)01 / KOSHY, Sandeep, Tharian
Novartis Institutes for Biomedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02142 / US
02 / CANHAM, Stephen, M.
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02142 / US
[N/P]
Former [2022/01]01 / KOSHY, Sandeep, Tharian
Cambridge, MA 02142 / US
02 / CANHAM, Stephen, M.
Cambridge, MA 02142 / US
Representative(s)Mathys & Squire
The Shard
32 London Bridge Street
London SE1 9SG / GB
[2022/01]
Application number, filing date20713456.024.02.2020
[2022/01]
WO2020US19461
Priority number, dateUS201962810260P25.02.2019         Original published format: US 201962810260 P
[2022/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020176397
Date:03.09.2020
Language:EN
[2020/36]
Type: A1 Application with search report 
No.:EP3930763
Date:05.01.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 03.09.2020 takes the place of the publication of the European patent application.
[2022/01]
Search report(s)International search report - published on:EP03.09.2020
ClassificationIPC:A61K47/69, A61K39/00, C12N15/86, C12N5/0783, A61K47/59, A61P35/00, A61P37/04
[2022/01]
CPC:
A61K47/6923 (EP,IL,KR,US); A61K38/1774 (US); A61K31/4745 (US);
A61K39/4611 (EP,IL,KR); A61K39/4631 (EP,IL,KR); A61K39/464404 (EP,IL,KR);
A61K39/464412 (EP,IL,KR); A61K39/464413 (EP,IL,KR); A61K39/464417 (EP,IL,KR);
A61K39/464424 (EP,IL,KR); A61K39/464429 (EP,IL,KR); A61K47/59 (EP,IL,KR,US);
A61K47/642 (US); A61K47/6901 (EP,IL,KR,US); A61K48/0066 (US);
A61K9/0019 (EP,IL,KR); A61K9/19 (EP,IL); A61K9/5115 (EP,IL,KR);
A61P35/00 (EP,IL,KR); A61P37/04 (EP,IL); C12N15/86 (US);
C12N5/0636 (EP,IL,KR,US); A61K2039/64 (KR); A61K2239/31 (EP,IL,KR);
A61K2239/48 (EP,IL,KR); C12N2501/2302 (US); C12N2501/51 (US);
C12N2501/515 (US); C12N2501/599 (US); C12N2510/00 (EP,IL,KR);
C12N2740/15043 (US); C12N2740/16043 (EP,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/01]
TitleGerman:ZUSAMMENSETZUNGEN MIT MESOPORÖSEN SILICIUMDIOXIDTEILCHEN ZUR VIRALEN VERABREICHUNG[2022/01]
English:MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY[2022/01]
French:COMPOSITIONS DE PARTICULES DE SILICE MÉSOPOREUSE POUR ADMINISTRATION VIRALE[2022/01]
Entry into regional phase02.09.2021National basic fee paid 
02.09.2021Designation fee(s) paid 
02.09.2021Examination fee paid 
Examination procedure02.09.2021Examination requested  [2022/01]
02.09.2021Date on which the examining division has become responsible
11.04.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
02.09.2021Renewal fee patent year 03
30.01.2023Renewal fee patent year 04
29.01.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[YDA]US2017051252  (MORGAN RICHARD [US], et al) [YD] 1-6,8-32,34-43,60-65,67-73 * paragraphs [0009] , [0044] , [0045] , [0053] , [0054] , [0086] , [0088] , [0229] , [0246] , [0251] , [0276] - [0279] - [0434] * [A] 7,66;
 [XD]WO2018013797  (HARVARD COLLEGE [US]) [XD] 96-99 * page 3, line 36 - page 4, line 19 * * page 5, lines 20-26 * * page 6, line 19 - page 7, line 21 * * page 7, line 22 - page 8, line 4 * * page 12, line 30 - page 13, line 5 * * page 98, line 29 - page 99, line 14 * * page 99, line 32 - page 100, line 7 *;
 [X]  - CHEUNG ALEXANDER S ET AL, "Scaffolds that mimic antigen-presenting cells enable expansion of primary T cells", NATURE BIOTECHNOLOGY, GALE GROUP INC., NEW YORK, US, vol. 36, no. 2, doi:10.1038/NBT.4047, ISSN 1087-0156, (20180115), pages 160 - 169, (20180115), XP036978439 [X] 96-99 * abstract * * figures 1(a),1(b) *

DOI:   http://dx.doi.org/10.1038/nbt.4047
 [XY]  - ANNA SLITA ET AL, "Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery", ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, NL, (20181101), vol. 13, no. 6, doi:10.1016/j.ajps.2018.01.006, ISSN 1818-0876, pages 592 - 599, XP055701297 [X] 100,102-107 * abstract * * figure 2 * [Y] 1-6,8-32,34-43,60-65,67-73

DOI:   http://dx.doi.org/10.1016/j.ajps.2018.01.006
 [XY]  - LI AILEEN WEIWEI ET AL, "A facile approach to enhance antigen response for personalized cancer vaccination", NATURE MATERIALS, NATURE PUB. GROUP, LONDON, vol. 17, no. 6, doi:10.1038/S41563-018-0028-2, ISSN 1476-1122, (20180305), pages 528 - 534, (20180305), XP036511188 [X] 100-107 * abstract * * page 532, column right, paragraph 2 - page 533, column left, line 3 * [Y] 25,27-59,74-95

DOI:   http://dx.doi.org/10.1038/s41563-018-0028-2
 [YA]  - AARON J. SMITH ET AL, "Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective", JOURNAL OF CELLULAR IMMUNOTHERAPY, (20161101), vol. 2, no. 2, doi:10.1016/j.jocit.2016.08.001, ISSN 2352-1775, pages 59 - 68, XP055445656 [Y] 1-6,8-32,34-43,60-65,67-73 * pages 61-64, section 2 "CAR T cell therapy" * * page 63; figure 1 * [A] 7,66

DOI:   http://dx.doi.org/10.1016/j.jocit.2016.08.001
 [Y]  - ANETT PFEIFFER ET AL, "T cells results in B-cell depletion and signs of cytokine release syndrome", EMBO MOLECULAR MEDICINE, (20180917), vol. 10, no. 11, doi:10.15252/emmm.201809158, ISSN 1757-4676, XP055701858 [Y] 25,27-59,74-95 * abstract *

DOI:   http://dx.doi.org/10.15252/emmm.201809158
 [Y]  - SAPRE AJAY A ET AL, "Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity", JOURNAL OF CONTROLLED RELEASE, (20190125), vol. 297, doi:10.1016/J.JCONREL.2019.01.034, ISSN 0168-3659, pages 48 - 59, XP085614626 [Y] 1-6,8-65,67-95 * abstract * * page 49, section 2.1 * * page 55, column right, paragraph 2 - page 56, column left, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2019.01.034
 [Y]  - TYREL T. SMITH ET AL, "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers", NATURE NANOTECHNOLOGY, London, (20170417), vol. 12, no. 8, doi:10.1038/nnano.2017.57, ISSN 1748-3387, pages 813 - 820, XP055536306 [Y] 1-6,8-32,34-43,60-65,67-73 * page 813, column left, paragraph last - column right, paragraph 2 * * figure 1 * * pages 819-820 "Conclusions" *

DOI:   http://dx.doi.org/10.1038/nnano.2017.57
by applicantFR901228
 US5395619
 US5637481
 US5786464
 US5837821
 US5864019
 US5869620
 US6114148
 US6703199
 US2005100543
 US2005175606
 WO2006020258
 US7083785
 US2007014794
 WO2007024715
 US2007049735
 US7446190
 US2011253643
 WO2012079000
 US2012256336
 US2012264599
 WO2012163805
 US2013052117
 US8399645
 US2013145488
 WO2013126712
 US2013273055
 WO2014055442
 WO2014055657
 WO2014130657
 WO2014130635
 WO2014153270
 US2014322212
 US2014322275
 US8883308
 US8920776
 US2015051266
 US2015072009
 US9034324
 WO2015090230
 US2015232557
 WO2015142675
 US2015284467
 US2015283178
 WO2015158671
 WO2015166073
 WO2015172800
 US2015344844
 WO2015188119
 US2015368351
 US9243058
 WO2016014565
 WO2016014535
 WO2016014576
 WO2016014789
 WO2016020332
 WO2016025880
 US2016046724
 WO2016028896
 US2016051651
 US9273141
 US2016068601
 US2016096892
 US2016131655
 US9340621
 WO2016079177
 WO2016090327
 WO2016090320
 WO2016087531
 WO2016094304
 US2016176973
 WO2016130598
 WO2016154055
 WO2016164731
 US2016297884
 US2016297885
 US2016368988
 WO2016210293
 WO2017011804
 WO2017008169
 WO2017021450
 WO2017025038
 US2017051308
 US2017051252
 US2017051068
 WO2017112741
 WO2018013797
 WO2018067992
 WO2019241426
    - HOLLINGERHUDSON, Nature Biotechnology, (20050000), vol. 23, pages 1126 - 1136
    - BIRD et al., Science, (19880000), vol. 242, pages 5879 - 5883
    - BATZER et al., Nucleic Acid Res., (19910000), vol. 19, page 5081
    - AL-LAZIKANI et al., JMB, (19970000), vol. 273, pages 927 - 948
    - MILONE et al., Mol. Ther., (20090000), vol. 17, no. 8, pages 1453 - 1464
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - REICHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - OHTSUKA et al., J. Biol. Chem., (19850000), vol. 260, pages 2605 - 2608
    - ROSSOLINI et al., Mol. Cell. Probes, (19940000), vol. 8, pages 91 - 98
    - SASTRY et al., J Virol., (20110000), vol. 85, no. 5, pages 1935 - 1942
    - BRENTJENS et al., Blood, (20110000), vol. 118, no. 18, pages 4817 - 4828
    - VERMA et al., J Immunol, (20100000), vol. 184, no. 4, pages 2156 - 2165
    - WILLEMSEN et al., Gene Ther, (20010000), vol. 8, no. 21, pages 1601 - 1608
    - DAO et al., Sci Transl Med, (20130000), vol. 5, no. 176, page 176ra33
    - TASSEV et al., Cancer Gene Ther, (20120000), vol. 19, no. 2, pages 84 - 100
    - HOFFMANN et al., Angewandte Chemie International Edition, (20060000), vol. 45, pages 3216 - 3251
    - KATIYAR et al., Journal of Chromatography, vol. 1122, no. 1-2, pages 13 - 20
    - WANG et al., Journal ofNanoparticle Research, (20130000), vol. 15, page 1501
    - AGGEN et al., Gene Ther., (20120000), vol. 1 -4, no. 4, pages 365 - 74
    - TOBIAS MAETZIG et al., "Gammaretroviral Vectors: Biology, Technology and Application", Viruses, (20110600), vol. 3, no. 6, pages 677 - 713
    - JUNE et al., Nature Reviews Immunology, (20090000), vol. 9.10, pages 704 - 716
    - LANZAVECCHIA et al., Eur. J. Immunol., (19870000), vol. 17, page 105
    - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
    - HOLLINGER et al., Proc Natl Acad. Sci. U.S.A., (19930000), vol. 90, pages 6444 - 6448
    - WILLEMSEN RA et al., Gene Therapy, (20000000), vol. 7, pages 1369 - 1377
    - ZHANG T et al., Cancer Gene Ther, (20040000), vol. 11, pages 487 - 496
    - XU et al., Leuk Lymphoma, (20120000), vol. 54, no. 2, pages 255 - 260
    - KOCHENDERFER et al., Blood, (20130000), vol. 122.17, no. 25, pages 2965 - 2973
    - KOCHENDERFER et al., Blood, (20100000), vol. 116, no. 20, pages 4099 - 102
    - XU et al., Blood, (20140000), vol. 123.24, pages 3750 - 9
    - NICHOLSON et al., Mol. Immun., (19970000), vol. 34, no. 16-17, pages 1157 - 1165
    - SMITH et al., "Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement", Clinical & Translational Immunology, (20150000), vol. 4, page e31
    - MILONE et al., Molecular Therapy, (20090000), vol. 17, no. 8, pages 1453 - 1464
    - BARRETT et al., Human Gene Therapy, (20110000), vol. 22, pages 1575 - 1586
    - J. Chem. Educ., (20170000), vol. 94, pages 91 - 94
    - New J. Chem., (20140000), vol. 38, page 3853
    - Langmuir, (20150000), vol. 31, pages 6457 - 6462
    - CHEUNG, A. S. et al., "Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells", Nature Biotechnology, vol. 36, no. 2, pages 160 - 169
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.